U.S. markets closed

Sio Gene Therapies, Inc. (SIOX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
2.64000.0000 (0.00%)
At close: 4:00PM EST

Sio Gene Therapies, Inc.

130 West 42nd Street
26th Floor
New York, NY 10036
United States
877 746 4891

Full Time Employees38

Key Executives

NameTitlePayExercisedYear Born
Dr. Pavan Cheruvu M.D.CEO & Director733.62kN/A1982
Mr. David W. NassifCFO & Gen. Counsel656.25kN/A1954
Dr. Gavin Corcoran FACP, M.D.Chief R&D Officer of Axovant Sciences, Inc.579.71kN/A1963
Dr. Parag V. Meswani Pharm.D.Chief Commercial OfficerN/AN/AN/A
Dr. Guangping GaoChief AAV Scientific AdvisorN/AN/AN/A
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Sio Gene Therapies, Inc., a clinical-stage gene therapy company, focuses on developing various product candidates for debilitating neurodegenerative diseases. The company's clinical-stage programs include AXO-Lenti-PD program for the treatment of Parkinson's disease; AXO-AAV-GM1 program for the treatment of GM1 gangliosidosis; and AXO-AAV-GM2 program for the treatment of GM2 gangliosidosis. It has a license agreement with Oxford BioMedica (UK) Ltd. and The University of Massachusetts Medical School. The company was formerly known as Axovant Gene Therapies Ltd. and changed its name to Sio Gene Therapies, Inc. in November 2020. Sio Gene Therapies, Inc. was founded in 2014 and is based in New York, New York.

Corporate Governance

Sio Gene Therapies, Inc.’s ISS Governance QualityScore as of December 2, 2020 is 9. The pillar scores are Audit: 5; Board: 10; Shareholder Rights: 1; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.